Omarigliptin

Omarigliptin (MK-3102) is a Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) drug used in the treatment of Type 2 diabetes. It was developed by Merck & Co. and approved in Japan in 2015. However, it has not been approved for use in the United States or Europe.

Mechanism of Action[edit | edit source]

Omarigliptin works by inhibiting the enzyme Dipeptidyl peptidase-4 (DPP-4). This enzyme is involved in the breakdown of Incretin hormones, which are responsible for increasing the amount of insulin released by the pancreas. By inhibiting DPP-4, Omarigliptin increases the levels of incretin hormones, leading to increased insulin release and decreased glucose levels in the blood.

Clinical Trials[edit | edit source]

Omarigliptin has undergone several clinical trials to assess its safety and efficacy in treating Type 2 diabetes. In a Phase III trial conducted in Japan, Omarigliptin was found to be effective in reducing HbA1c levels in patients with Type 2 diabetes.

Approval[edit | edit source]

Omarigliptin was approved for use in Japan in September 2015. However, in 2016, Merck & Co. announced that they would not seek approval for Omarigliptin in the United States or Europe, citing a desire to focus on other drugs in their portfolio.

Side Effects[edit | edit source]

Common side effects of Omarigliptin include Nausea, Headache, and Upper respiratory tract infection. In rare cases, it can cause Pancreatitis and Hypoglycemia.

See Also[edit | edit source]

Omarigliptin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.